IT HAS taken a while, but on 6 June the US Food and Drug Administration announced the diabetes drug Avandia will soon come with a prominent “black box” warning about the risk of congestive heart failure. Experts reviewing the drug for the FDA first called for one over a year ago. Some say the delay is another example of industry versus science, with science the loser.
“Some say the delay is another example of industry versus science, with science the loser”
An oral drug that lowers blood sugar, GlaxoSmithKline’s Avandia has been used by patients with type 2 diabetes since…
